An interventional study of ITB Titration Protocol and Ventral Dorsal Rhizotomy in Dystonic Cerebral Palsy, sponsored by Baylor College of Medicine. Recruiting at 1 site in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Baylor College of Medicine · Not applicable, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing baclofen in Muscle Spasticity — 2 open to participants now, 3 under way, none of them phase 3. Baclofen · Muscle Spasticity.
Among the 10 studies testing baclofen in Muscle Spasticity, this one is the 4th largest by planned enrollment, is the only one that started in 2024, is one of 3 with no phase, and was the 8th registered.
626 studies on the registry are indexed under Muscle Spasticity; 131 are open to participants now.
Browse Muscle Spasticity studies →2 of the 10 studies testing baclofen in Muscle Spasticity are open now, in 2 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18+
By country, each count listing its studies:
Baclofen: first FDA approval 1977 (LIORESAL). What it is approved for, and how studies give it, is on its page →
Of the 88 Muscle Spasticity studies recruiting now, 29 (33%) set no upper age limit and 47 (53%) stop at 75 or younger; 34 take children under 18; 11 take healthy volunteers.
This study: Up to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 1 · Phase 4 3
First in 2005; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 65 is above the median of 36 across 477 interventional studies indexed under Muscle Spasticity.
Median enrollment 61 across the 10 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 9 most frequent:
Baylor College of Medicine is the lead sponsor of 747 studies on the registry; 110 are open to participants now.
Of its 84 completed or terminated interventional studies of FDA-regulated products, 45 (54%) have results posted.
Baylor College of Medicine has 1 study filed under Muscle Spasticity — fewer than ten, so there is no comparison to draw.
1 of the studies testing baclofen in Muscle Spasticity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07792616University of Mississippi Medical CenterElectrical Neuromodulation for Modifying Spinal Network Involved in Spasticity | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing baclofen in Muscle Spasticity, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to better understand outcomes in children with dystonic cerebral palsy (CP) receiving intrathecal baclofen (ITB), ventral dorsal rhizotomy (VDR), or deep brain stimulation (DBS) as part of standard clinical care. The decision to proceed with ITB, VDR, or DBS is made independently of research participation.
The study aims to:
Participants receiving ITB will follow a study-specific standardized titration protocol designed to identify a dose that provides maximum benefit with minimal side effects. Participants in all three groups will complete research assessments and questionnaires at protocol-specified timepoints to evaluate dystonia, spasticity, function, pain, stress, and quality of life.
Cerebral palsy (CP) is the most common cause of physical disability in childhood and affects \~1 in 323 in the US per the CDC. The lifetime medical costs for an individual with CP was expected to be \~$1.4 million (inflation adjusted). An effective way to improve quality of life and decrease disease burden, both in childhood and adulthood, is to significantly reduce or eliminate abnormal tone. As muscle tone subsides, it is easier to move the body both passively and actively. A reduction in tone can improve quality of life, reduce pain, ease the burden of daily care and performance of day-to-day activities, and reduce healthcare costs. Intrathecal baclofen ( ITB) is used widely to manage dystonia in CP even though the data on exact efficacy is mixed. Therefore, the goal of this study, is to understand the effects of ITB on a heterogenous population of children with dystonic CP.
The goal of the proposed research is to complete a longitudinal prospective cohort study investigating the effects of intrathecal baclofen (ITB) on children with dystonic cerebral palsy (CP). This study builds on new preliminary data and capitalizes on the expertise of an established transdisciplinary team, a high-resource academic clinical environment, and a diverse Parent-Patient Council. The study's findings are likely to have high impact to improve future treatment of children with dystonic CP, including identifying key patient characteristics associated with more or less positive outcomes and developing a sensitive, efficient multidimensional composite measure to assess treatment responsiveness. Specifically, this protocol aims to determine the 12-month effects of ITB in a cohort of 65 clinically representative, ITB naïve, children with dystonic CP using a standardized titration protocol. Additionally, this protocol aims to complete a detailed characterization of brain malformation and injury patterns in children with dystonic CP and explore potential differences in outcome patterns as related to patient characteristics and use findings to guide development of a sensitive multidimensional or composite measure that captures clinically important areas of change for the child and family.
The criteria were revised on the registry on Nov 5, 2026. See what changed
Inclusion Criteria for pre-implant ITB subjects:
Inclusion Criteria for post-implant ITB subjects:
Inclusion criteria for VDR subjects:
Inclusion criteria for DBS subjects:
Exclusion Criteria:
Participants in this arm receive intrathecal baclofen (ITB) as part of standard clinical care. The decision to proceed with ITB is made independently of research participation. Enrolled participants follow a study-specific ITB titration protocol and complete research assessments and study monitoring at protocol-specified timepoints.
Drug: ITB Titration Protocol · Other: Research Assessments and Study Monitoring
Participants in this arm undergo ventral dorsal rhizotomy (VDR) as part of standard clinical care. The decision to proceed with VDR is made independently of research participation. The study does not assign participants to VDR or modify the VDR procedure or clinical follow-up. Enrolled participants complete research assessments and study monitoring at baseline and 3, 6, and 12 months.
Procedure: Ventral Dorsal Rhizotomy · Other: Research Assessments and Study Monitoring
Participants in this arm undergo deep brain stimulation (DBS) as part of standard clinical care. The decision to proceed with DBS is made independently of research participation. The study does not assign participants to DBS or modify the DBS procedure or clinical follow-up. Enrolled participants complete research assessments and study monitoring at baseline and 3, 6, and 12 months.
Procedure: Deep Brain Stimulation · Other: Research Assessments and Study Monitoring
Intrathecal baclofen (ITB) is provided as part of standard clinical care, and the decision to proceed with ITB is made independently of research participation. Enrolled participants follow a study-specific standardized titration protocol. ITB dose is increased according to prespecified steps based on persistent hypertonia and/or potential improvement on the D-FIS, provided there are no detrimental side effects. Titration continues until dystonia and spasticity are eliminated or no longer deemed functionally impairing by the medical team, side effects limit further titration, or a maximum dose of 2,000 mcg/day is reached. If detrimental side effects occur, the dose is reduced to the previous step as needed until side effects are controlled. The final tolerated dose becomes the maintenance dose for the remainder of the study.
Also known as: Intrathecal Baclofen
Ventral dorsal rhizotomy (VDR) is performed as part of standard clinical care. The decision to proceed with VDR is made independently of research participation. The study does not assign participants to VDR or modify the VDR procedure or clinical follow-up.
Deep brain stimulation (DBS) is performed as part of standard clinical care. The decision to proceed with DBS is made independently of research participation. The study does not assign participants to DBS or modify the DBS procedure or clinical follow-up.
Participants complete protocol-specified clinician or therapy assessments, patient-reported outcome measures, and study-monitoring activities at baseline and 3, 6, and 12 months. For participants receiving ITB, selected assessments and safety-monitoring activities also occur during study-specific titration visits.
Barry-Albright Dystonia Scale (BADS)
The BADS was created based on the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS), a tool originally designed to detect cervical dystonia in adults.The BADS tailors this scale for detecting dystonia in CP and acquired brain injury in individuals with limitations in cognition and physical ability. Scoring focuses on posturing and involuntary dystonic movements to detect potential changes in dystonia that affect ease of care and comfort. It does not assess functional tasks. It has moderate internal consistency and inter-rater reliability. It has effectively detected change with ITB. The BADS was also found to have the greatest clinical utility for children with dystonic CP
Time frame: Baseline (pre-intervention), 3 months, 6 months, and 12 months
Dyskinesia Impairment Scale-II (DIS-II)
The DIS-II is one of the newest scales to measure dystonia and choreoathetosis at rest and during activity. It is unique in separating choreoathetosis from dystonia in this population. It has moderate internal consistency and fair interrater reliability. We include this measure because it was a key measure in the IDYS trial by Bonouvrie LA et al., the single RCT trial, thus permitting direct comparison across our studies.
Time frame: Baseline (pre-intervention), 3 months, 6 months, and 12 months
Australian Spasticity Assessment Scale (ASAS) and Composite Measure
The ASAS combines the best aspects of the MTS with the simplicity of the MAS's scoring system. It has clear instructions on how the limb must be tested while supine to increase reproducibility. Its interrater reliability is very high with a weighted kappa of 0.87, making it ideal for a large study with multiple time points. We will generate a composite score (as well have individual scores) for key muscle groups.
Time frame: Baseline (pre-intervention), 3 months, 6 months, and 12 months
Modified Ashworth Scale (MAS)
While our study relies strongly on the ASAS, we will also measure MAS so our data can be compared across studies.
Time frame: Baseline (pre-intervention), 3 months, 6 months, and 12 months
Gross Motor Family Report (GMFR)
The Gross Motor Function Report (GMFR) is a patient- or caregiver-reported measure that evaluates gross motor abilities and functional mobility in everyday activities. The GMFR assesses performance across a range of movement domains, including sitting, standing, transfers, walking, running, and participation in daily physical activities. Higher scores indicate better gross motor function and mobility.
Time frame: Baseline (pre-intervention), 3 months, 6 months, and 12 months
Box and Blocks Test
This test is a quick, simple way to assess manual dexterity. This test cannot be used in a child with severe upper extremity impairment or severe cognitive impairment, therefore, not all participants in this study will be able to complete this task. A child is asked to move as many blocks as possible from one side of a divided box to the other in 60 seconds. It has excellent interrater reliability and MCID of 5.29- 6.46 seconds.
Time frame: Baseline (pre-intervention), 3 months, 6 months, and 12 months
Performance Quality Rating Scale (PQRS)
The PQRS is an observational measure of performance quality of a parent/patient-selected meaningful activity. Occupational therapists use a video recording of a child performing the task of interest and then rate the quality. It has high interrater reliability from 0.83-0.93 and test-retest reliability \>0.80.
Time frame: Baseline (pre-intervention), 3 months, 6 months, and 12 months
Canadian Occupational Performance Measure (COPM)
The COPM focuses on occupational performance in all areas of life, including self-care, leisure, and productivity. It consists of a semi- structured interview to determine areas of concern for the parent and child. Together with an occupational therapist, they score performance on the particular concerns at the set timepoints in the study. We will have families and children set 2-3 goals that are relevant to ITB treatment. The COPM is an excellent tool for this study as it is very sensitive to change and has an established MCID of 2 points.
Time frame: Baseline (pre-intervention), 3 months, 6 months, and 12 months
Caregiver Priorities & Child Health Index of Life with Disabilities (CPCHILD©)
The CPCHILD© measures a child with severe disability's overall health, comfort, function, and QoL in relationship to their medical conditions. It has 37 questions answered by the child or parent about activities of daily living, positioning, transferring and mobility, comfort and emotions, communications and social interaction, health, and overall QoL. It was initially validated in children with CP and traumatic brain injuries. Prospective longitudinal cohort studies are underway to assess the measure's responsiveness/sensitivity to change.
Time frame: Baseline (pre-intervention), 3 months, 6 months, and 12 months
Patient-Reported Outcomes Measurement Information System (PROMIS®) Questionnaires
NIH's Office of Strategic Coordination - Common Fund's PROMIS® developed a validated item bank of patient-reported outcomes for clinical research and practice. The PROMIS offers many short form questionnaires that are simple and quick for parents and children to complete. We will use the following to assess pain, anxiety, depression, and stress: (1a) PROMIS® Pediatric Item Bank v1.0 - Pain Behavior 8a (1b) PROMIS® Parent Proxy Bank v1.0 - Pain Behavior 8a. (2a) PROMIS® Pediatric Item Bank v2.0 - Pediatric Anxiety - Short Form 8a (2b) Parent Proxy Bank v2.0 - Parent Proxy Anxiety - Short Form 8a (3a) PROMIS® Pediatric Item Bank v2.0 - Pediatric Depressive Symptoms - Short Form 8a (3b) Parent Proxy Bank v2.0 - Parent Proxy Depressive Symptoms - Short Form 6a. (4) PROMIS® Parent Proxy Bank v1.0 - Psychological Stress Experiences - Short Form 4a. (5) PROMIS® Parent Proxy Bank v1.0 - Physical Stress
Time frame: Baseline (pre-intervention), 3 months, 6 months, and 12 months
Goal Attainment Scale (GAS)
The GAS is a unique outcome measurement tool with some controversy about its standardization. It selects a single important goal to be tracked before, during, and after an intervention. GAS was created to account for the heterogeneity of the rehabilitation population. In addition to choosing the goal(s), the child and their family, with guidance from their care team, choose how to define a successful outcome. GAS is tailored to each child and has been shown to be as sensitive to change over time as other standard outcome measurement tools, including the GMFM (discussed above) and the Pediatric Evaluation of Disability Inventory. The single RCT IDYS trial used the GAS as their 1o outcome measure. By including this, we can directly compare results.
Time frame: Baseline (pre-intervention), 3 months, 6 months, and 12 months
Manual Ability Classification System (MACS)
The Manual Ability Classification System (MACS) is a 5-level classification system that describes how children and adolescents with cerebral palsy use their hands to handle objects in daily activities. Level I indicates independent handling of objects with ease, while Level V indicates severe limitations requiring total assistance. Higher MACS levels reflect greater impairment in manual ability.
Time frame: Baseline (pre-intervention), 3 months, 6 months, and 12 months
Communication Function Classification System (CFCS)
The Communication Function Classification System (CFCS) is a 5-level classification system that describes the everyday communication performance of individuals with cerebral palsy. It classifies how effectively a person sends and receives messages with familiar and unfamiliar communication partners. Level I indicates effective communication with all partners, while Level V indicates seldom effective communication even with familiar partners. Higher CFCS levels reflect greater communication limitations.
Time frame: Baseline (pre-intervention), 3 months, 6 months, and 12 months
Eating and Drinking Ability Classification System (EDACS)
The Eating and Drinking Ability Classification System (EDACS) is a 5-level classification system that describes how safely and efficiently individuals with cerebral palsy eat and drink. Level I indicates safe and efficient eating and drinking, while Level V indicates inability to eat or drink safely, with significant assistance required. Higher EDACS levels reflect greater limitations in eating and drinking ability.
Time frame: Baseline (pre-intervention), 3 months, 6 months, and 12 months
Plan to share: Undecided — Individual Participant data and final study results may be reviewed with the participant(s) and their families. Data de-identified data may be summarized into graphs showing the changes in all of the measures at 0, 3, 6, and 12 months.
Started Nov 2024 (actual). Primary completion is estimated for Jun 2029, 55 months after the start.
Of 228 non-industry interventional studies with no phase under Muscle Spasticity, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 37. This study's planned 55 months is above that.
Counting every sponsor, half of 236 studies reached it within 15 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baclofen